The University of Birmingham in the UK is set to launch the CATALYST trial this week to evaluate various drugs for the treatment of Covid-19 patients.
CATALYST will involve drugs targeting the most serious symptoms. This mechanism is expected to mitigate disease severity, decreasing the number of patients requiring intensive care admission.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
A series of new drugs will be tested in the trial, including existing medicines for cancer and inflammatory diseases such as rheumatoid arthritis.
